Back to Results

Affimed NV (AFMDQ)

Affimed N.V. is a clinical-stage biopharmaceutical company focused on cancer immunotherapies, with research and development activities in the United States and Germany. The company’s pipeline includes AFM13, which has completed Phase 2 studies in CD30-positive lymphoma and peripheral T-cell lymphoma and has also been evaluated in a Phase Ib study in Hodgkin lymphoma. Its other programs include AFM24, a bispecific innate cell engager in Phase IIa development for advanced cancers, as well as AFM28 and AFM32, which are in preclinical development for acute myeloid leukemia and solid tumors, respectively. Affimed has entered into collaborations with Artiva Biotherapeutics, Roivant Sciences, and Genentech to advance selected product candidates and immunotherapy programs. The company, founded in 2000 and headquartered in Mannheim, Germany, was formerly known as Affimed Therapeutics B.V. and adopted its current name in 2014.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Market Cap
OTC-AFMD.Q	Not available	Not available	Not available	Weak	0.0%	November 12, 2026	1.639 K

Smart Snapshot

Stock Overview

A fast read of the company and market metrics currently supported by the latest data.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Quality & Risk

Financial Health

Weak

Upcoming Events

Next Earnings Date

November 12, 2026

Days to Earnings

Valuation • Fair Value

Affimed NV (OTC-AFMD.Q) Fair Value by Valuation Model

No usable valuation estimate is currently available for Affimed NV (OTC-AFMD.Q); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Affimed NV (OTC-AFMD.Q). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Affimed NV (OTC-AFMD.Q)

Review the profitability and growth indicators currently supported by the latest data.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Affimed NV (OTC-AFMD.Q) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Affimed NV (OTC-AFMD.Q)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Affimed NV (OTC-AFMD.Q). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Affimed NV (OTC-AFMD.Q)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Affimed NV (OTC-AFMD.Q), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Affimed NV (OTC-AFMD.Q) Stock Forecast & Technical Outlook

Review Affimed NV (OTC-AFMD.Q) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy

Time frame: daily • daily

Neutral

The daily technical read for Affimed NV (OTC-AFMD.Q) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy

Time frame: weekly • weekly

Sell

The weekly technical read for Affimed NV (OTC-AFMD.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy

Time frame: monthly • monthly

Strong Sell

The monthly technical read for Affimed NV (OTC-AFMD.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Affimed NV (OTC-AFMD.Q)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy

Consolidated analyst recommendation mix

Hold

Based on the available recommendation mix, Affimed NV (OTC-AFMD.Q) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0

Hold 1

Sell 0

FAQ • Fast Investor Answers

Affimed NV (OTC-AFMD.Q) Stock FAQ

Data-supported answers about Affimed NV (OTC-AFMD.Q), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value

Not available

No reliable estimate from the currently supported inputs

Financial Health

Weak

Current financial-health read

A reliable fair value estimate is not currently available for Affimed NV (OTC-AFMD.Q). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Affimed NV (OTC-AFMD.Q) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Affimed NV (OTC-AFMD.Q) is November 12, 2026.

The latest available data indicates no current dividend yield for Affimed NV (OTC-AFMD.Q).

The current market capitalization listed for Affimed NV is 1.639 K.

The ticker symbol for Affimed NV is OTC-AFMD.Q, and the stock is listed on OTC Markets.

Affimed NV (OTC-AFMD.Q) is listed on OTC Markets.